BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

616 related articles for article (PubMed ID: 16456867)

  • 1. Comparison between pimonidazole binding, oxygen electrode measurements, and expression of endogenous hypoxia markers in cancer of the uterine cervix.
    Jankovic B; Aquino-Parsons C; Raleigh JA; Stanbridge EJ; Durand RE; Banath JP; MacPhail SH; Olive PL
    Cytometry B Clin Cytom; 2006 Mar; 70(2):45-55. PubMed ID: 16456867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced expression of hypoxia-inducible factor-1alpha in perinecrotic regions of solid tumors.
    Sobhanifar S; Aquino-Parsons C; Stanbridge EJ; Olive P
    Cancer Res; 2005 Aug; 65(16):7259-66. PubMed ID: 16103077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia biomarkers in squamous cell carcinoma of the uterine cervix.
    Ellingsen C; Andersen LM; Galappathi K; Rofstad EK
    BMC Cancer; 2015 Oct; 15():805. PubMed ID: 26502718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1alpha-related markers, and hemoglobin levels.
    Bache M; Reddemann R; Said HM; Holzhausen HJ; Taubert H; Becker A; Kuhnt T; Hänsgen G; Dunst J; Vordermark D
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1481-7. PubMed ID: 17056190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, HIF-1α, CAIX, LDH-5, GLUT-1, MCT1 and MCT4.
    Rademakers SE; Lok J; van der Kogel AJ; Bussink J; Kaanders JH
    BMC Cancer; 2011 May; 11():167. PubMed ID: 21569415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoxia-inducible factor 1alpha expression as an intrinsic marker of hypoxia: correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of the cervix.
    Hutchison GJ; Valentine HR; Loncaster JA; Davidson SE; Hunter RD; Roberts SA; Harris AL; Stratford IJ; Price PM; West CM
    Clin Cancer Res; 2004 Dec; 10(24):8405-12. PubMed ID: 15623619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding.
    Airley RE; Loncaster J; Raleigh JA; Harris AL; Davidson SE; Hunter RD; West CM; Stratford IJ
    Int J Cancer; 2003 Mar; 104(1):85-91. PubMed ID: 12532423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical detection of changes in tumor hypoxia.
    Russell J; Carlin S; Burke SA; Wen B; Yang KM; Ling CC
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1177-86. PubMed ID: 19251089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical detection of HIF-1alpha and CAIX in advanced head-and-neck cancer. Prognostic role and correlation with tumor markers and tumor oxygenation parameters.
    Kappler M; Taubert H; Holzhausen HJ; Reddemann R; Rot S; Becker A; Kuhnt T; Dellas K; Dunst J; Vordermark D; Hänsgen G; Bache M
    Strahlenther Onkol; 2008 Aug; 184(8):393-9. PubMed ID: 18956515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endogenous markers of tumor hypoxia predictors of clinical radiation resistance?
    Vordermark D; Brown JM
    Strahlenther Onkol; 2003 Dec; 179(12):801-11. PubMed ID: 14652668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of hypoxia-inducible factor-1alpha (HIF-1alpha) as an intrinsic marker of tumor hypoxia in U87 MG human glioblastoma: in vitro and xenograft studies.
    Vordermark D; Brown JM
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):1184-93. PubMed ID: 12829158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia in larynx carcinomas assessed by pimonidazole binding and the value of CA-IX and vascularity as surrogate markers of hypoxia.
    Hoogsteen IJ; Lok J; Marres HA; Takes RP; Rijken PF; van der Kogel AJ; Kaanders JH
    Eur J Cancer; 2009 Nov; 45(16):2906-14. PubMed ID: 19699082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detecting changes in tumor hypoxia with carbonic anhydrase IX and pimonidazole.
    Shin KH; Diaz-Gonzalez JA; Russell J; Chen Q; Burgman P; Li XF; Ling CC
    Cancer Biol Ther; 2007 Jan; 6(1):70-5. PubMed ID: 17172824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of HIF-1α and CAIX in nasopharyngeal carcinoma and their correlation with patients' prognosis.
    Chen Y; Li X; Wu S; Xu G; Zhou Y; Gong L; Li Z; Yang D
    Med Oncol; 2014 Dec; 31(12):304. PubMed ID: 25377659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endogenous hypoxia markers in locally advanced cancers of the uterine cervix: reality or wishful thinking?
    Mayer A; Höckel M; Vaupel P
    Strahlenther Onkol; 2006 Sep; 182(9):501-10. PubMed ID: 16944371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of CAIX and CAXII Expression in Breast Cancer at Varied O2 Levels: CAIX is the Superior Surrogate Imaging Biomarker of Tumor Hypoxia.
    Tafreshi NK; Lloyd MC; Proemsey JB; Bui MM; Kim J; Gillies RJ; Morse DL
    Mol Imaging Biol; 2016 Apr; 18(2):219-31. PubMed ID: 26276155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer.
    Olive PL; Aquino-Parsons C; MacPhail SH; Liao SY; Raleigh JA; Lerman MI; Stanbridge EJ
    Cancer Res; 2001 Dec; 61(24):8924-9. PubMed ID: 11751418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of HIF-1alpha expression in patients with definitive radiotherapy for cervical cancer.
    Dellas K; Bache M; Pigorsch SU; Taubert H; Kappler M; Holzapfel D; Zorn E; Holzhausen HJ; Haensgen G
    Strahlenther Onkol; 2008 Mar; 184(3):169-74. PubMed ID: 18330514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA damage is a prerequisite for p53-mediated proteasomal degradation of HIF-1alpha in hypoxic cells and downregulation of the hypoxia marker carbonic anhydrase IX.
    Kaluzová M; Kaluz S; Lerman MI; Stanbridge EJ
    Mol Cell Biol; 2004 Jul; 24(13):5757-66. PubMed ID: 15199132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential risk assessments from five hypoxia specific assays: The basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients.
    Nordsmark M; Eriksen JG; Gebski V; Alsner J; Horsman MR; Overgaard J
    Radiother Oncol; 2007 Jun; 83(3):389-97. PubMed ID: 17499868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.